Pds biotech announces preliminary safety data on pds0101 in combination with keytruda® (pembrolizumab) at the 2022 multidisciplinary head and neck cancers symposium

Preliminary safety data has shown that pds0101 in combination with merck's anti-pd-1 therapy, keytruda® (pembrolizumab) for the treatment of recurrent or metastatic hpv16-positive head and neck cancer is likely safe and well tolerated without evidence of enhanced or significant toxicity
PDSB Ratings Summary
PDSB Quant Ranking